论文部分内容阅读
目的:针对急性ST段抬高型心肌梗死,重点分析选用阿替普酶溶栓治疗这种疾病的治疗效果。方法:选取2013年7月-2014年7月于本院治疗ST段抬高型心肌梗死患者126例,依据随机原则分为对照组(使用尿激酶)与治疗组(使用阿替普酶),分别63例,比较两组治疗效果。结果:对照组胸痛缓解21例(33.33%)、溶栓后再通14例(22.22%)显著低于治疗组胸痛缓解45例(71.43%)、溶栓后再通49例(77.49%);对照组不良反应7例(9.52%)显著高于治疗组不良反应2例(3.17%);依据心电图ST段回落情况,可知治疗组:>50%回落发生率为79%、完全回落51%均高于对照组,差异具有统计学意义(P<0.05)。结论:阿替普酶治疗急性ST段抬高型心肌梗死患者具有不良反应少、安全性强,比尿激酶的冠脉开通几率更高,不单纯受制院内条件限制,具有临床使用价值。
Objective: Acute ST elevation myocardial infarction, focusing on the use of alteplase thrombolytic therapy for the treatment of this disease. Methods: Totally 126 patients with ST-elevation myocardial infarction were treated in our hospital from July 2013 to July 2014. According to the randomized principle, the patients were divided into control group (using urokinase) and treatment group (using alteplase) 63 cases were compared, the treatment effect of two groups were compared. Results: 21 cases (33.33%) had relieve chest pain in the control group, 14 cases (22.22%) thrombolyzed after thrombolysis were significantly lower than 45 cases (71.43%) in the treatment group and 49 cases (77.49%) after the thrombolysis. In the control group, 7 patients (9.52%) had adverse reactions, which were significantly higher than those in the treatment group (3.17%). According to the fall of the ST segment in the electrocardiogram, the incidence of> 50% Higher than the control group, the difference was statistically significant (P <0.05). CONCLUSION: Altreplase in patients with acute ST-segment elevation myocardial infarction has fewer adverse reactions, higher safety and higher probability of coronary artery opening than urokinase, which is not limited by the hospital conditions and has clinical value.